Table 1.
Baseline Characteristics Ascertained 6 Months Prior to Index Date of the Overall Cohort and by Stent Type
| Overall (N=7474) | DES (N=4979) | BMS (N=2495) | |
|---|---|---|---|
| Demographics | |||
| Age, mean (SD), y | 60.1 (11.5) | 60.1 (11.3) | 60.2 (12.0) |
| Male | 50.8 | 49.4 | 53.6 |
| Race | |||
| White | 55.6 | 57.0 | 52.9 |
| Black | 36.1 | 34.5 | 39.4 |
| Asian | 5.7 | 6.0 | 5.2 |
| Other/Unknown | 2.5 | 2.6 | 2.4 |
| Peritoneal dialysis | 4.9 | 5.0 | 4.8 |
| Time since end‐stage renal disease, median (IQR), years | 3.4 (1.7 to 5.9) | 3.3 (1.7 to 5.7) | 3.6 (1.9 to 6.4) |
| Cause of end‐stage renal disease | |||
| Diabetes | 62.0 | 65.4 | 55.1 |
| Hypertension | 23.8 | 21.8 | 27.8 |
| Glomerulonephritis | 5.7 | 5.0 | 7.3 |
| Other/unknown | 8.5 | 7.8 | 9.9 |
| Non‐nephrology outpatient visits, median (IQR) | 22 (13 to 33) | 22 (13 to 34) | 21 (12 to 32) |
| Hospital days, median (IQR) | 3 (1 to 10) | 3 (1 to 10) | 4 (1 to 11) |
| Any nursing home stay | 6.5 | 6.3 | 7.0 |
| On kidney transplant waiting list | 17.2 | 17.2 | 17.2 |
| Multivessel intervention | 19.0 | 20.9 | 15.2 |
| Index presentation | |||
| Stable coronary artery disease | 62.6 | 63.6 | 60.7 |
| ST elevation myocardial infarction | 5.6 | 4.5 | 7.7 |
| Non‐ST elevation myocardial infarction | 31.4 | 31.5 | 31.2 |
| Unstable angina | 0.4 | 0.4 | 0.4 |
| Year of revascularization | |||
| 2007 | 15.0 | 13.4 | 18.4 |
| 2008 | 29.2 | 28.6 | 30.5 |
| 2009 | 28.1 | 29.4 | 25.7 |
| 2010 | 27.6 | 28.7 | 25.5 |
| Cardiovascular comorbidities | |||
| PCI prior to index | 27.9 | 30.2 | 23.2 |
| CABG prior to index | 24.3 | 24.7 | 23.6 |
| Myocardial infarction | 30.7 | 30.3 | 31.3 |
| Angina | 46.6 | 47.7 | 44.5 |
| Heart failure | 78.0 | 78.0 | 78.1 |
| Hypertension | 100.0 | 100.0 | 100.0 |
| Atrial fibrillation | 21.9 | 21.2 | 23.3 |
| Other arrhythmia | 28.3 | 27.8 | 29.2 |
| Stroke/transient ischemic attack | 28.6 | 28.4 | 29.2 |
| Valvular disease | 42.0 | 40.7 | 44.7 |
| Peripheral arterial disease | 60.3 | 60.6 | 59.8 |
| Cerebrovascular disease | 28.8 | 28.9 | 28.7 |
| Other comorbid conditions | |||
| Diabetes mellitus | 87.3 | 89.1 | 83.6 |
| Hyperlipidemia | 83.3 | 84.5 | 80.8 |
| Gastrointestinal bleeding | 32.6 | 31.5 | 35.0 |
| Peptic ulcer disease | 9.8 | 9.4 | 10.7 |
| Intracranial hemorrhage | 2.9 | 2.6 | 3.4 |
| Liver disease | 21.0 | 20.2 | 22.7 |
| Chronic lung disease | 52.4 | 51.5 | 54.2 |
| Smoking history | 22.8 | 20.5 | 27.3 |
| Dementia | 8.5 | 8.2 | 9.1 |
| Depression | 30.5 | 30.6 | 30.4 |
| Cancer | 12.2 | 11.4 | 13.6 |
| Hypothyroid | 19.9 | 20.2 | 19.4 |
| Obesity | 24.5 | 24.9 | 23.7 |
| Baseline medication use | |||
| Thienopyridine | 36.1 | 40.0 | 28.3 |
| Other antiplatelet agents | 3.2 | 3.1 | 3.4 |
| Anticoagulants | 9.8 | 9.0 | 11.5 |
| Non‐steroidal anti‐inflammatory | 9.2 | 9.3 | 8.9 |
| Angiotensin converting enzyme inhibitors | 41.3 | 41.4 | 41.1 |
| Angiotensin II receptor blockers | 23.6 | 24.1 | 22.6 |
| Beta blockers | 74.5 | 74.9 | 73.7 |
| Calcium channel blockers | 56.7 | 57.5 | 55.3 |
| Central alpha receptor blocker | 26.4 | 25.9 | 27.4 |
| Alpha blocker | 5.8 | 5.6 | 6.3 |
| Diuretics | 23.8 | 24.9 | 21.7 |
| Nitrates | 32.9 | 33.4 | 31.9 |
| Vasodilators | 25.0 | 24.8 | 25.6 |
| Statins | 56.9 | 58.8 | 53.2 |
| Other lipid‐lowering agents | 15.1 | 16.0 | 13.2 |
| Proton pump inhibitors | 50.6 | 50.7 | 50.3 |
| Census region | |||
| Pacific | 15.0 | 16.0 | 13.1 |
| Mountain | 4.6 | 5.0 | 3.8 |
| West North Central | 5.1 | 5.0 | 5.5 |
| East North Central | 15.0 | 14.0 | 16.9 |
| Mid Atlantic | 12.8 | 13.5 | 11.6 |
| Northeast | 2.6 | 2.2 | 3.4 |
| West South Central | 16.6 | 16.6 | 16.5 |
| East South Central | 8.4 | 8.7 | 7.8 |
| South Atlantic | 19.9 | 19.2 | 21.4 |
All values are % unless otherwise noted. BMS indicates bare metal stent; CABG, coronary artery bypass grafting; DES, drug‐eluting stent; IQR, interquartile range; PCI, percutaneous coronary intervention; SD, standard deviation.